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Abstract Calcium channel antagonists have been reported to
have a favorable impact on cyclosporin A (CsA)-treated kidney
transplant recipients. However, it is not clear whether this is
because of their direct effect on antagonizing the toxicity of CsA
to renal tubular cells. In this study, we have used Madin^Darby
canine kidney tubular cells as a model to examine the effect of
diltiazem, a calcium channel antagonist, on CsA-induced
apoptosis. Moreover, to investigate the possible regulation of
CsA cytotoxicity by intracellular calcium level, the effect of the
calcium ionophore A23187 on CsA-induced apoptosis was also
examined. We found that treatment of CsA (20 WM) alone
caused 20^30% cell death, which was apparently (30^40%)
enhanced by diltiazem at 100 Wg/ml, accompanied by more severe
DNA fragmentation, activation of caspases, and a decreased
level of Bcl-2. The caspase inhibitor ZVAD-fmk or Bcl-2
overexpression was capable of suppressing apoptosis induced by
the synergistic effect of diltiazem and CsA. Moreover, the
survival rate of cells treated with CsA (30 WM) alone remained
only 30%, however, it was markedly (V40%) elevated by co-
treatment with A23187 (75 ng/ml). The rescue of cells from CsA-
induced apoptosis by A23187 was correlated with AKT
activation, BAD phosphorylation, and caspase-3 inactivation.
Taken together, our results suggest that the reported favorable
impact of diltiazem on kidney grafts is likely not because of its
direct protection on renal tubular cells. Instead, it enhances the
toxicity of CsA to renal tubular cells. In addition, our findings
raise a possibility that the intracellular calcium level and the
AKT pathway may participate in the regulation of CsA
cytotoxicity. ß 2002 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
The immunosuppressive agent cyclosporin A (CsA) is
widely used for the management of organ transplantation
and in the treatment of various autoimmune disorders [1].
However, its adverse e¡ect on renal structure and function
makes nephrotoxicity a major limiting side e¡ect [2]. Chronic
CsA nephrotoxicity can progress to an irreversible lesion char-
acterized by tubular atrophy, loss of tubular cells, and inter-
stitial ¢brosis [3,4]. The pathogenesis of chronic CsA nephro-
toxicity has been thought to be secondary to the
hemodynamic changes elicited by the intense e¡ect of CsA
on vasoconstriction [5]. However, increasing evidence also in-
dicates that CsA has a direct toxicity to renal tubular cells,
leading to their apoptosis [6]. An increased rate of tubular cell
apoptosis was observed in human renal biopsy specimens ob-
tained from patients with CsA nephrotoxicity [7]. In rats [8,9]
or in vitro cell culture [10,11], CsA has been shown to induce
tubular cell apoptosis, correlated with the activation of the
caspase cysteine proteases and the altered expression of pro-
or anti-apoptotic proteins, such as p53, the Bcl-2 family pro-
teins, and Fas/Fas-L proteins.
From animal studies and few clinical reports [12^16], it
appears that the calcium channel antagonists, such as diltia-
zem and verapamil, have a favorable impact on CsA-treated
kidney transplant recipients. Although the detailed mecha-
nism is not clear, one of the possibilities is that calcium
channel antagonists may have a direct ‘cytoprotective’ e¡ect
on renal tubular cells. In this study, we set out to examine
this possibility in Madin^Darby canine kidney (MDCK)
cells.
2. Materials and methods
2.1. Chemicals
CsA was purchased from Novartis Pharmaceutical. Diltiazem HCl
(Herbesser0) was purchased from Tanabe Seiyaku Co. (Osaka, Ja-
pan). Calcium ionophore A23187 was purchased from Calbiochem
(San Diego, CA, USA). Caspase inhibitor ZVAD-fmk was purchased
from Takara Shuzo Co. (Shiga, Japan). The monoclonal anti-Bcl-2
was purchased from Transduction Laboratories (Lexington, KY,
USA). The rabbit polyclonal anti-AKT, anti-phosphoAKT (Ser473),
and anti-cleaved caspase-3 and the monoclonal anti-phosphoBAD
(Ser112) were purchased from New England Biolabs (Beverly, MA,
USA).
2.2. Cell culture
MDCK cells were obtained from American Type Culture Collec-
tion and maintained in Dulbecco’s modi¢ed Eagle’s medium (Life
Technologies) supplemented with 10% fetal bovine serum and cul-
tured at 37‡C in a humidi¢ed atmosphere of 5% CO2 and 95% air
atmosphere. MDCK cells stably overexpressing Bcl-2 have been de-
scribed previously [17]. Cells were seeded at 3U105 per 60-mm culture
disk in growth medium for 36 h before pharmacological treatments.
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To examine the e¡ect of diltiazem on CsA cytoxicity, cells were
treated simultaneously with 20 WM CsA and various doses (mostly
100 Wg/ml) of diltiazem for 24 h. To examine the e¡ect of A23187 on
CsA cytoxicity, cells were pretreated with various doses (mostly 75 ng/
ml) of A23187 for 1 h before CsA addition to 30 WM. Those cells were
further incubated for 24 h before analysis. In some experiments, cells
were pretreated with the caspase inhibitor ZVAD-fmk at 60 WM for
1 h before CsA addition.
2.3. Measurements of cell survival, DNA fragmentation, and caspase
activity
Cell viability was determined by trypan blue exclusion. Brie£y,
CsA-treated cells including both £oating and adhesive cells were col-
lected and washed once with phosphate-bu¡ered saline (PBS). Cell
suspensions in PBS were mixed with an equal volume of 0.4% trypan
blue (Sigma) and cells excluding dye were counted with a hemocy-
tometer under a light microscope. Cell survival was expressed as the
percentage of live cells remaining after 24 h CsA treatment compared
to the cell number at the time right before CsA addition.
To measure the extent of DNA fragmentation, cells were collected
as described above and subjected to a colorimetric enzyme immuno-
assay for determination of histone-associated DNA fragments using a
Cell Death Detection ELISAPLUS kit (Boehringer Mannheim) follow-
ing the manufacturer’s instructions. Each experiment was performed
in duplicate.
The activities of caspase-1, 2, 3, 4, 8, 9, and 10 were measured by
Caspase Colorimetric Protease Assay kits from BioVision Research
Products (Palo Alto, CA, USA) following the manufacturer’s instruc-
tions. Each experiment was performed in duplicate.
2.4. Immunoblotting
24 h after CsA treatment, cells were washed twice with PBS and
lysed in 1% Nonidet P-40 lysis bu¡er (1% Nonidet P-40, 20 mM Tris^
HCl, pH 8.0, 137 mM NaCl, 10% glycerol, and 1 mM Na3VO4)
containing protease inhibitors as described previously [18]. The lysates
were centrifuged for 10 min at 4‡C to remove debris, and the protein
concentrations were determined using the Bio-Rad Protein Assay
(Hercules, CA, USA). The lysates (50 Wg) were subjected to sodium
dodecyl sulfate^polyacrylamide gel electrophoresis, and transferred to
nitrocellulose (Schleicher and Schuell, Keene, NH, USA). Immuno-
blotting was performed with appropriate antibodies using the NEN
Life Science chemiluminescence system for detection.
2.5. Statistics
Statistical analyses were performed with a simple t-test. Di¡erences
were considered to be statistically signi¢cant at P6 0.05.
3. Results
3.1. Enhancement of renal cytotoxicity of CsA by calcium
channel antagonist diltiazem
To examine whether calcium channel antagonists have a
protective e¡ect on CsA-induced cell death, MDCK cells
were treated with 20 WM CsA in the presence or absence of
the L-type calcium channel antagonist diltiazem for 24 h (Fig.
1A). CsA alone induced 20^30% cell death. In the combined
treatment of CsA with lower concentrations (1 and 10 Wg/ml)
of diltiazem, the rate of cell death remained constant. How-
ever, the rate of cell death was 15 and 30% increased when
diltiazem was at 50 and 100 Wg/ml, respectively. It is note-
worthy that diltiazem at 100 Wg/ml had no detectable toxicity
to MDCK cells within 24 h. Moreover, in time-course experi-
ments (Fig. 1B), we found that within 24 h, CsA in combina-
tion with 100 Wg/ml diltiazem constantly led to V30% more
cell death than CsA alone did. Together, although adminis-
tration of diltiazem has been reported to bene¢t CsA-treated
kidney transplant recipients [13^16], our results clearly dem-
onstrate that the toxicity of CsA to renal tubular cells is
enhanced by diltiazem in vitro.
3.2. Diltiazem enhancement of CsA-induced cell death results
from increased apoptosis
CsA has previously been shown to induce apoptosis via
caspase-dependent pathway in renal tubular cells [9,10]. To
examine if caspases are involved in diltiazem enhancement
of CsA-induced cell death, a broad range caspase inhibitor,
ZVAD-fmk, was applied in the experiments (Fig. 1A). ZVAD-
fmk at 60 WM signi¢cantly suppressed cell death induced by
20 WM CsA and 100 Wg/ml diltiazem, suggesting a possible
involvement of caspases in diltiazem-enhanced cell death. To
further examine the possibility that diltiazem potentiates the
e¡ect of CsA on apoptosis, the extent of DNA fragmentation,
a characteristic of apoptosis, was measured using a colorimet-
Fig. 1. Enhancement of renal cytotoxicity of CsA by calcium chan-
nel antagonist diltiazem. A: MDCK cells were treated with (+) or
without (3) 20 WM CsA in the presence of various concentrations
of diltiazem as indicated. In one case, the broad range caspase in-
hibitor ZVAD-fmk (60 WM) was added to the culture 1 h before
CsA addition. 24 h after CsA addition, live cells were determined
by trypan blue exclusion. Cell survival is expressed as the percent-
age of live cells remaining compared with the cell number at the
time right before CsA addition. Data (means þ S.E.M.) are from
three independent experiments. *P6 0.001 (statistically signi¢cant
compared with CsA alone). **P6 0.001 (statistically signi¢cant
compared with combined treatment of CsA and 100 Wg/ml diltia-
zem). B: MDCK cells were treated with CsA (20 WM) alone or in
combination with diltiazem (100 Wg/ml). After various times as indi-
cated, cell survival was determined as described in A. Data (means
þ S.E.M.) are from three independent experiments.
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ric method (Fig. 2A). In accordance with the results in Fig.
1A, the extent of DNA fragmentation in cells treated with
CsA and diltiazem was much more evident than that in cells
treated with CsA alone. In addition, ZVAD-fmk e¡ectively
prevented the occurrence of DNA fragmentation induced by
CsA and diltiazem. These results together indicate that en-
hancement of CsA-induced cell death by diltiazem is mainly
through apoptosis. Next, the activation of caspases by CsA
and diltiazem was measured using a colorimetric method,
which determines the fold of increase in caspase activity com-
pared to untreated cells (Fig. 2B). The caspases examined in
our experiments all exhibited an increase in their activities. Of
these, caspase-3 had the highest increase in its activity, con-
sistent with its role as an executioner in apoptosis [19]. Be-
cause the cleavage of caspase-3 by other upstream caspases is
required for its activation, the active form of caspase-3 was
analyzed by immunoblotting with an antibody against the
cleaved caspase-3 (Fig. 2C). More active caspase-3 was de-
tected in cells treated with both CsA and diltiazem than in
cells treated with CsA alone, suggesting a role of caspase-3 in
apoptosis induced by CsA and diltiazem.
3.3. Overexpression of anti-apoptotic protein Bcl-2 suppresses
cell death induced by CsA and diltiazem
The function of Bcl-2 is important to suppress mitochon-
dria-dependent apoptosis [20^22]. To examine whether Bcl-2
is capable of suppressing apoptosis induced by both CsA and
diltiazem, stable MDCK cell lines overexpressing Bcl-2 were
established. As shown in Fig. 3A, the expression level of ec-
topic Bcl-2 is at least 10-fold higher than that of endogenous
Bcl-2. In addition, on treatment of CsA and diltiazem, a de-
Fig. 2. Diltiazem enhancement of CsA-induced cell death results
from increased apoptosis. A: MDCK cells were pretreated with (+)
or without (3) ZVAD-fmk (60 WM) for 1 h before additions of
CsA (20 WM) and/or diltiazem (100 Wg/ml). 24 h later, the extent of
histone-associated DNA fragments was measured using a colorimet-
ric enzyme-immunoassay kit from Promega. The absorbance was
measured at 405 nm against substrate solution as a blank at 490
nm. Experiments were performed in duplicate. Data (mean-
s þ S.E.M.) are from three independent experiments. *P6 0.001 (sta-
tistically signi¢cant compared with CsA alone). **P6 0.001 (statisti-
cally signi¢cant compared with combined treatment of CsA and
diltiazem). B: MDCK cells were treated with or without the treat-
ment of CsA (20 WM) and diltiazem (100 Wg/ml). 24 h later, the ac-
tivation of caspases was measured by colorimetric protease assay
kits from BioVision. Relative activation of caspases is expressed as
-fold increase compared to the level of caspase activity in control
cells without treatments of CsA and diltiazem. Data are the average
from two independent experiments. C: MDCK cells were treated as
described in A and lysed. Equal amount of lysates was analyzed by
immunoblotting with a polyclonal antibody recognizing cleaved cas-
pase-3. The result shown is the representative of three independent
experiments.
Fig. 3. Overexpression of Bcl-2 suppresses cell death induced by
CsA and diltiazem. A: MDCK cells stably overexpressing Bcl-2 and
a control clone (Neo) were treated with CsA alone or in combina-
tion with diltiazem for 24 h. Cell lysates were prepared and ana-
lyzed by immunoblotting with anti-Bcl-2. The result shown is the
representative of three independent experiments. B: MDCK cells
were treated as described in A and their survival was determined by
trypan blue exclusion. Data (means þ S.E.M.) are from three inde-
pendent experiments. *P6 0.05 (statistically signi¢cant compared
with CsA-treated Neo cells). **P6 0.001 (statistically signi¢cant
compared with Neo cells treated with CsA and diltiazem).
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creased level of endogenous Bcl-2 was observed in control
neomycin-resistant cells (Neo), suggesting that inhibition of
Bcl-2 expression and/or cleavage of Bcl-2 protein may con-
tribute to apoptosis induced by CsA and diltiazem. In addi-
tion, the survival rate of MDCK cells overexpressing Bcl-2
was approximately 30% higher than that of control cells in
the presence of CsA and diltiazem (Fig. 3B). Together with
the results in Fig. 2, it is likely that diltiazem enhancement of
CsA-induced apoptosis may be mitochondria- and caspase-
dependent.
3.4. Attenuation of CsA cytotoxicity by calcium ionophore
A23187
Because diltiazem is a calcium channel antagonist, which
presumably prevents the in£ux of calcium from the outside
of the cell and at least transiently decreases intracellular cal-
cium level, we were interested to know whether the cytotox-
icity of CsA is attenuated when the intracellular calcium is
increased. To examine this possibility, the calcium ionophore
A23187, which increases the intracellular calcium, was applied
to the experiments (Fig. 4). The cell survival rate of MDCK
cells remained only approximately 30% after 24-h treatment
with 30 WM CsA. To our surprise, the cell survival was ele-
vated by A23187 and most prominent when its concentration
was 75 ng/ml. Moreover, in time-course experiments, 18 and
24 h after CsA treatment, the survival rate of cells with
A23187 was signi¢cantly (V40%) higher than that of cells
without A23187.
3.5. Suppression of CsA-induced DNA fragmentation and
caspase-3 activation by calcium ionophore A23187,
correlated with activation of the AKT pathway
To further con¢rm the e¡ect of A23187 on attenuation of
CsA cytotoxicity, the extent of DNA fragmentation and cas-
pase-3 activation was measured. As shown in Fig. 5A, A23187
had a protective e¡ect against CsA-induced DNA fragmenta-
tion, concomitant with a decrease in caspase-3 activation in a
dose-dependent manner. The AKT pathway has been known
to be a major pathway for cell survival [23^25]. To investigate
whether the activation of AKT is involved in A23187 attenu-
ation of CsA-induced apoptosis, lysates from cells treated
with CsA alone or in combination with various doses of
A23187 were analyzed for Ser473 phosphorylation of AKT,
which serves as an indicator for AKT activation (Fig. 5B).
Correlated with its ability to induce apoptosis, the treatment
of CsA markedly resulted in dephosphorylation of AKT.
More importantly, this dephosphorylation of AKT by CsA
was prevented by A23187 in a dose-dependent manner, which
was concomitant with phosphorylation of a pro-apoptotic
protein, BAD. Taken together, these results suggest that cal-
cium ionophore A23187 may suppress CsA-induced apoptosis
through the AKT pathway.
4. Discussion
In this study, we have used renal tubular MDCK cells as a
model to examine the e¡ect of two calcium metabolism mod-
ulators, diltiazem, a calcium channel antagonist, and A23187,
a calcium ionophore, on the cytotoxicity of CsA. As in other
tubular epithelial cells [10,11], CsA induced apoptosis in
MDCK cells, characterized by DNA fragmentation and acti-
vation of caspases (Fig. 2). More importantly, we showed that
the CsA-induced apoptosis was enhanced by diltiazem and, in
contrast, attenuated by A23187, suggesting a possible regula-
tion of CsA cytotoxicity by intracellular calcium level. In ad-
dition, the results that the tetrapeptide caspase inhibitor
ZVAD-fmk (Fig. 2) or the overexpression of the anti-apopto-
tic protein Bcl-2 (Fig. 3) was capable of inhibiting apoptosis
induced by the combined treatment of CsA and diltiazem
support the involvement of caspases and mitochondria in dil-
tiazem enhancement of CsA-induced apoptosis.
The pathogenesis of CsA nephrotoxicity has been inten-
sively studied, which associates with endothelial injury, acti-
vation of the intrarenal rennin angiotensin system, and depo-
sition of extracellular matrix [26]. The endothelin-mediated
renal vasoconstriction has been suggested to play an impor-
tant role in endothelial cell injury and the toxicity caused by
CsA [27]. Therefore, it has been proposed that the favorable
impact of diltiazem on CsA-treated kidney transplant recipi-
ents may be because of its e¡ect on improving the glomerular
hemodynamics and its protective e¡ect on endothelium [13^
Fig. 4. Attenuation of CsA cytotoxicity by calcium ionophore
A23187. A: MDCK cells which had been pretreated with various
concentrations of A23187 for 1 h were treated with (+) or without
(3) 30 WM CsA. 24 h later, cell survival was determined by trypan
blue exclusion. Data (means þ S.E.M.) are from three independent
experiments. When compared with CsA alone, the di¡erences at 50,
75 and 100 ng/ml of A23187 are statistically signi¢cant. *P6 0.05.
**P6 0.001. B: MDCK cells were treated with CsA (30 WM) alone
or in combination with A23187 (75 ng/ml). After various times as
indicated, cell survival was determined by trypan blue exclusion.
Data (means þ S.E.M.) are from three independent experiments.
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16]. Nevertheless, in this study we clearly demonstrated in
vitro that diltiazem enhances the toxicity of CsA to renal
tubular cells without consideration of endothelial e¡ect. In
fact, our results are consistent with a previous report [28]
that verapamil, a calcium channel antagonist, potentiates
rather than reduces the CsA toxicity. Thus, it is unlikely
that the advantage of diltiazem in CsA-treated patients is
through its direct ‘cytoprotective’ e¡ect on renal tubular cells.
Based on the assumptions described above, we propose that
diltiazem may enhance the apoptotic toxicity to renal tubular
cells caused by CsA in patients with endothelial dysfunction.
In addition to hemodynamic mechanism, diltiazem may pro-
tect renal tissue by other mechanisms. For example, it may
in£uence hepatic CsA metabolism and promote an increased
accumulation of CsA metabolites such as M17 [29^31]. The
increased level of the metabolite M17 was found to correlate
with a decreased number of rejection episode [32], however,
the nephrotoxic properties and the immunological activity of
the metabolite M17 remain to be de¢ned.
Alternatively, diltiazem may exert its advantage in CsA-
treated patients by enhancing immunosuppression. This pos-
sibility is based on our assumption that diltiazem may en-
hance the toxicity of CsA not only to renal tubular cells but
also to lymphocytes. From this point of view, the synergistic
e¡ect of diltiazem and CsA on causing apoptosis in lympho-
cytes could enhance immunosuppression, thereby decreasing
the incidence of acute and chronic rejection of kidney allo-
grafts. On the other hand, it could directly cause more severe
damage in renal tubular cells, leading to chronic transplant
nephropathy. Because available clinical data to these issues
are few, it remains uncertain whether administration of diltia-
zem, in the long run, is advantageous to CsA-treated kidney
transplant recipients. More studies will be necessary to eluci-
date the long-term e¡ect of calcium channel antagonists on
renal transplantation.
Although the mechanism of CsA-induced apoptosis in renal
tubular cells is unclear, it appears to involve activation of
caspases and altered expression of proteins critical for the
control of apoptosis, such as p53, the Bcl-2 family proteins,
and Fas/Fas-L proteins [9,11]. In this study, we show the ¢rst
time that the treatment of CsA led to inactivation of the Ser/
Thr protein kinase AKT, accompanied by decreased phos-
phorylation of its downstream target BAD (Fig. 5B). The
pro-apoptotic protein BAD has been shown to dimerize
with Bcl-2 and Bcl-XL, thereby inhibiting the ability of Bcl-
2 and Bcl-XL to block the release of cytochrome c from mi-
tochondria, a critical step in the activation of the downstream
caspase protease cascade [21,33,34]. Thus, although the mech-
anism for CsA to inactivate AKT is currently unknown, our
¢nding provides a possible explanation for CsA to activate
caspases, as described in this report and elsewhere [9,10].
Moreover, we found that, correlated with its ability to rescue
cells from CsA-induced apoptosis, the calcium ionophore
A23187 prevented the CsA-caused inactivation of AKT
through an unknown mechanism, concomitant with increased
phosphorylation of BAD (Fig. 5). This ¢nding accords with
the notion that phosphorylated BAD by activated AKT is
translocated from the mitochondria to the cytosol through
its association with 14-3-3, allowing Bcl-XL to exert its func-
tion as a gatekeeper of cytochrome c e¥ux at mitochondria
membrane and to promote cell survival [35,36]. Recently, For-
noni et al. [37] reported that CsA induces a decreased level of
Bcl-XL and apoptosis in a murine podocyte cell line, which
can be prevented by hepatocyte growth factor through the
AKT pathway.
In T lymphocytes, calcium initiates the proliferative re-
sponse by stimulating various transcription factors such as
NF-UB, NFAT, and CREB. One action of calcium is to stim-
ulate the calcium-dependent protein phosphatase calcineurin
to dephosphorylate NFAT, which then enters the nucleus [38].
CsA blocks the calcineurin-dependent dephosphorylation of
NFAT through its inhibitory e¡ect on calcineurin [39,40]. It
is not known whether in renal tubular cells, the calcineurin/
NFAT pathway is a target of CsA and whether its inactiva-
tion by CsA contributes to CsA-induced apoptosis. Recently,
Huang et al. [41] showed that vanadium activates NFAT in
mouse ¢broblasts or epidermal cells, which can be inhibited
by a calcium channel antagonist, nifedipine, and enhanced by
two calcium ionophores, A23187 and ionomycin. Their results
Fig. 5. Suppression of CsA-induced DNA fragmentation and cas-
pase-3 activation by calcium ionophore A23187, correlated with ac-
tivation of the AKT pathway. A: MDCK cells which had been pre-
treated with various doses of A23187 for 1 h were treated with (+)
or without (3) 30 WM CsA. 24 h later, the extent of histone-associ-
ated DNA fragments was measured using a colorimetric enzyme im-
munoassay kit from Promega. The absorbance was measured at 405
nm against substrate solution as a blank at 490 nm. Experiments
were performed in duplicate. Data (means þ S.E.M.) are the average
of two independent experiments. When compared with CsA alone,
the di¡erences at 25, 50, 75 and 100 ng/ml of A23187 are statistical-
ly signi¢cant. *P6 0.001. To detect the cleaved caspase-3, equal
amount of cell lysates was analyzed by immunoblotting with poly-
clonal anti-cleaved caspase-3. B: Cell lysates were prepared from
the cells as described in A and analyzed by immunoblotting with
anti-phosphoBAD, anti-phosphoAKT, and anti-AKT. The results
shown are the representative of three independent experiments.
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suggest a possible role of intracellular calcium in NFAT acti-
vation in non-lymphocytes. Experiments are in progress to
examine the e¡ects of CsA and calcium metabolism modula-
tors on NFAT activation and its link with CsA-induced apo-
ptosis in renal tubular cells.
In summary, this in vitro study indicates that diltiazem
enhances the apoptosis of renal tubular cells caused by CsA
and suggests that the inhibition of the AKT pathway may be
critical for CsA to induce apoptosis.
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